Cardinal Health has signed agreements to manufacture and package Tamiflu for Roche to help meet current and future demand for the influenza medicine, which is recommended by the World Health Organization as a frontline treatment against a potential pandemic avian flu outbreak. Under the terms of the manufacturing agreement, Cardinal will manufacture 75 mg hard gelatin capsules of Tamiflu on behalf of Roche at one of Cardinal’s manufacturing sites in Europe. The companies also have arr...